How Can Clinical Trials Improve Diversity? CTM’s Cara Brant Explains
Historically, clinical trials have under-represented women and minorities. Clinical Trial Media's Cara Brant offers ...
How Do You Know If a Clinical Trial Is Right for You?
You're thinking of participating in a clinical trial – what now? Ask questions and weigh the risks before deciding if a clinical trial is right for you.
Vaccine targeting pancreatic cancer shows promise in new study of clinical trial
A clinical trial from Memorial Sloan Kettering Cancer Center looked at the effects of a targeted mRNA vaccine on early-stage ...
Enrollment Initiated for Phase 2 Clinical trial in Early Alzheimer’s with Sinaptica’s Second-Generation Precision Neuromodulation System
Sinaptica Therapeutics, Inc., a clinical-stage company leading the development of a new class of personalized neuromodulation ...
Bantam Pharmaceutical Announces Activation of First Phase 1 Clinical Trial Site at MD Anderson Cancer Center
Bantam Pharmaceutical, a drug discovery and development company targeting selective modulation of mitochondrial dynamics in ...
Business Wire1mon
Segal Trials Leads Phase 2 Schizophrenia Trial of LB-102 Toward Primary Endpoint
--(BUSINESS WIRE)--Segal Trials, a privately held clinical research network specializing ... Segal Trials and investigator on the Phase 2 trial. “LB-102 study data is very encouraging and ...
Septerna Announces Discontinuation of SEP-786 Phase 1 Clinical Trial and Plans to Advance Next-Generation Oral Small Molecule PTH1R Agonist
Trial decision follows unanticipated events of elevated unconjugated bilirubin levelsCompany advancing multiple next-generation PTH1R agonists ...
Macau Business15d
Anti-HER2 Bispecific ADC JSKN003 Received Approval to Initiate a Phase III Clinical Study for the Treatment of HER2-positive Breast Cancer
(“CSPC”) (Stock Code: 1093.HK) jointly announced that anti-HER2 biparatopic antibody-drug conjugate (ADC) JSKN003 has received approval from the Center for Drug Evaluation (CDE) of the National ...
manilatimes2d
IMUNON Announces Translational Data from Phase 1/2 OVATION 2 Study of IMNN-001 in Advanced Ovarian Cancer
Data reinforce dose-dependent mechanism with IMNN-001 100mg/m 2 dose associated with 20% increase in IL-12 levels compared to 79mg/m 2 dose. Results from OVATION 2 Study continue ...